Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1326-1331

  Yoshioka, H ^a   Okamoto, I ^b   Morita, S ^c   Ando, M ^d   Takeda, K ^e   Seto, T ^f   Yamamoto, N ^g   Saka, H ^h   Atagi, S ⁱ   Hirashima, T ^j   Kudoh, S ^k   Satouchi, M ^l   Ikeda, N ^m   Iwamoto, Y ⁿ   Sawa, T ^o   Nakanishi, Y ^p   Nakagawa, K ^b  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^j OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^k OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l HYOGO CANCER CENTER   (Japan)

^m TOKYO MEDICAL UNIVERSITY   (Japan)

ⁿ HIROSHIMA CITY HOSPITAL   (Japan)

^o Gifu Municipal Hospital   (Japan)

^p KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Carboplatin; Histology; Non small cell lung cancer; S 1; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; TS 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; THROMBOCYTOPENIA;

EID: 84877125989     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds629     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
3. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
4. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
5. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
6. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010; 11: 121-128.
7. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
8. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
9. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
10. Kwak EL, Bang YJ, Camidge R et al. Anaplastic lymphoma kinase inhibitor in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
11. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-2606.
12. Okamoto I, Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 290-294.
13. Okamoto I, Yoshioka H, Morita S et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a West Japan Oncology Group study. J Clin Oncol 2010; 28: 5240-5246.
14. Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
15. Cella D, Peterman A, Hudgens S et al. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003; 98: 822-831.
16. National Comprehensive Cancer Network Inc. NCCN Practice Guidelines in Oncology; Non-Small Cell Lung Cancer-v.3., 2012; http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf (20 August 2012, data last accessed).
17. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
18. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated nonsmall-cell lung cancer. New Engl J Med 2005; 353: 123-132.
19. Hayashi H, Okamoto I, Morita S et al. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 1537-1541.
20. Kaneda H, Urata Y, Okamoto I et al. Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemo-naïve patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: e18060.